EUCTR2007-003080-45-GB
Active, not recruiting
Phase 1
Phase ll study evaluating the toxicity and efficacy of a modified German Paediatric Hodgkin's Lymphoma protocol (HD95) in young adults (aged 18-30 years) with Hodgkin's Lymphoma - 18-30 Study
niversity College London0 sites0 target enrollmentSeptember 3, 2007
ConditionsMedical condition under investigation is known as Hodgkin's disease, which is a cancer of the lymphatic system. It is usually treated with either chemotherapy or radiotherapy or a combination of both.MedDRA version: 14.0 Level: LLT Classification code 10020328 Term: Hodgkin's lymphoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Medical condition under investigation is known as Hodgkin's disease, which is a cancer of the lymphatic system. It is usually treated with either chemotherapy or radiotherapy or a combination of both.
- Sponsor
- niversity College London
- Status
- Active, not recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Biopsy proven de novo calssical Hodgkin's lymphoma
- •2\) No previous chemotherapy or radiotherapy
- •3\) Age 18\-30 years
- •4\) Any stage
- •5\) Able to give informed consent
- •6\) Agreement to take adequate precautions to prevent conception during chemo\-/radiotherapy and for up to one year afterwards
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
Exclusion Criteria
- •1\) Nodular Lymphocyte Predominant Hodgkin's disease
- •2\) Previous chemotherapy or radiotherapy
- •3\) Known or suspected HIV infection
- •4\) Pre\-existing neurological disorder
- •5\) Serious co\-morbidity which may prevent administration of study treatment
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
To evaluate the impact of PET scan based radiotherapy planning for cervical cancer in Indian women.Health Condition 1: null- Carcinoma cervixCTRI/2016/05/006924Department of Biotechnology Government of India60
Active, not recruiting
Not Applicable
Phase II study evaluating the toxicity and activity of the combination lapatinib + capecitabine in elderly patients aged 70 and over with metastatic breast cancer over expressing HER2ocally advanced or metastatic breast cancer over expressing HER2 and = 70 years oldMedDRA version: 12.0Level: LLTClassification code 10055113Term: Breast cancer metastaticMedDRA version: 12.0Level: LLTClassification code 10048406Term: Breast cancer aggravatedEUCTR2009-015981-73-FRFNCLCC (Fédération Nationale des Centres de Lutte Contre le Cancer)
Not yet recruiting
Phase 2
To study the efficacy of a ayurvedic polyherbal preparation (Carctol-S) in patients with recurrent ovarian cancer.CTRI/2019/02/017873Central Council for Research in Ayurvedic Sciences Ministry of AYUSH Government of India
Active, not recruiting
Not Applicable
A Phase II Study to evaluate activity and toxicity of Gemcitabine in Combination with Pemetrexed long term infusion in the Treatment of pretreated Metastatic Colorectal Cancer PatientsPretreated patients with advanced colorectal cancerMedDRA version: 14.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2010-019841-25-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI
Recruiting
Phase 2
Phase II study evaluating the efficacy and safety of the Bevacizumab / Docetaxel maintenance therapy beyond stable disease in patients with advanced relapsed non-squamous NSCLC who received Bevacizumab / pemetrexed / platinum induction therapyJPRN-UMIN000010055Respiratory Center, Showa University Northern Yokohama Hospital20